These figures are pretty accurate. Remember Tobramycin powder is now replacing TOBI solution, so that is a factor. The other response was not accurate. Arikace will be on the market in two years because of NTM.
Gilead's cystic fibrosis drug Cayston =Analysts predict that Cayston MAY achieve annual sales of $161.7 million by 2014. TOBI sales last year were aprx 75M. Wedbush predicted 35-45 M for Arikace,if approved by 2018.(2019 with delay of trial)